SCHEMBL4722536

SCHEMBL4722536

Nc1c(-c2cccnc2)sc2cnccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 7/20 0.47
CYP3A4 P08684 5/20 0.47
CYP2E1 P05181 4/20 0.47
CYP2C9 P11712 4/20 0.47
CYP2B6 P20813 4/20 0.47
CYP2D6 P10635 3/20 0.47
CYP2C19 P33261 3/20 0.47
KDM4E B2RXH2 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
HTT P42858 2/20 0.44
HSD17B10 Q99714 2/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
NCOA1 Q15788 1/20 0.44
RCE1 Q9Y256 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5620698 0.89 ALDH1A1 (0.46) CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6
SCHEMBL4724741 0.76 KDM4E (0.53) CYP3A4CYP2C9CYP2D6CYP2C19KDM4E
SCHEMBL19587052 0.73 GAA (0.53) CYP2A6CYP3A4CYP2C9CYP2D6CYP2C19
SCHEMBL4722564 0.73 BRAF (0.50) CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6
Hydrochloric Acid SCHEMBL28051932 0.72 GAA (0.51) CYP2A6CYP3A4CYP2C9CYP2D6CYP2C19
SCHEMBL657642 0.69 BRAF (0.42) KDM4EALDH1A1HPGDHTTHSD17B10
SCHEMBL9868855 0.69 ALOX5 (0.45) KDM4EALDH1A1HPGDHTTHSD17B10
SCHEMBL11885002 0.68 KDM4E (0.44) CYP2A6CYP3A4CYP2C9CYP2D6CYP2C19
SCHEMBL27812368 0.67 CYP2A6 (0.94) CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6
SCHEMBL4765086 0.67 KDM4E (0.50) CYP2A6CYP3A4CYP2C9CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934228-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2008-06-25 EP disclosed
WO-2007027855-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2007-03-08 WO disclosed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof BRAF, RAF1, ARAF CYP2A6 3712/4885CYP3A4 3785/4885CYP2E1 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.